Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has 7 years of Operating Leases data on file, last reported at $24.0 million in Q4 2025.

• On a quarterly basis, Operating Leases fell 20.0% year-over-year to $24.0 million in Q4 2025; TTM through Dec 2025 was $24.0 million, a 20.0% decrease from a year earlier, with the FY2025 full-year figure at $24.0 million, down 20.0% from the prior year.
• Operating Leases for Q4 2025 stood at $24.0 million, up from $21.7 million in the prior quarter.
• Over the last five years, Operating Leases for RARE reached as high as $36.8 million in Q1 2021 and fell as low as $14.8 million in Q2 2023.
• Historically, Operating Leases has averaged $26.8 million across 5 years, with a median of $26.8 million in 2022.
• Across the five-year window, Operating Leases tumbled 42.69% in 2023 and surged 73.4% in 2024, its largest moves.
• Year by year, Operating Leases stood at $30.9 million in 2021, then sank by 35.89% to $19.8 million in 2022, then soared by 54.31% to $30.6 million in 2023, then retreated by 1.88% to $30.0 million in 2024, then declined by 20.0% to $24.0 million in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $24.0 million in Q4 2025, $21.7 million in Q3 2025, and $24.5 million in Q2 2025.